Chemomab Therapeutics (CMMB) Liabilities and Shareholders Equity (2017 - 2025)

Chemomab Therapeutics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $13.8 million for Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 18.58% year-over-year to $13.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $50.1 million (down 28.81% YoY) and the FY2025 annual result came in at $13.8 million, down 18.58% from the prior year.
• Liabilities and Shareholders Equity was $13.8 million for Q4 2025 at Chemomab Therapeutics, up from $12.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $70.5 million in Q2 2021 and bottomed at $11.1 million in Q2 2025.
• A 5-year average of $35.2 million and a median of $26.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 777.1% — and 2023, when it slumped 53.37%.
• Chemomab Therapeutics' Liabilities and Shareholders Equity stood at $64.4 million in 2021, then sank by 33.08% to $43.1 million in 2022, then plunged by 48.56% to $22.2 million in 2023, then decreased by 23.42% to $17.0 million in 2024, then decreased by 18.58% to $13.8 million in 2025.
• Business Quant data shows CMMB's Liabilities and Shareholders Equity at $13.8 million in Q4 2025, $12.4 million in Q3 2025, and $11.1 million in Q2 2025.